Epilepsy Treatment Advances with Positive Results from Three Cannabis-Based Drug Trials


Michael Privitera, MD, speaks at a 2016 patient symposium presented by
the UC Epilepsy Center. Photo by Cindy Starr.

The coming year is likely to include a milestone in the treatment of severe epilepsy: a formal request that the U.S. Food and Drug Administration approve a drug derived from marijuana.

Epidiolex, made from purified cannabidiol, a compound in the marijuana (cannabis) plant, will be submitted to the FDA for approval soon, says Michael Privitera, MD, director of the Epilepsy Center at the University of Cincinnati Gardner Neuroscience Institute and immediate past president of the American Epilepsy Society. He predicts the drug could be approved as early as 2018.

“Three major trials have shown positive results,” Privitera says. “This is a very important advance in the treatment of epilepsy.”

The UC Epilepsy Center was one of 20 sites involved in a Phase 3 clinical study of Epidiolex for the treatment of adults with Lennox-Gastaut syndrome, a serious type of epilepsy that usually begins in childhood and involves multiple types of seizures. People with Lennox-Gastaut can experience hundreds of seizures per week. The seizures, which come without warning, are associated with falls and developmental delay.

Two other major trials involved Epidiolex as a treatment for children with Lennox-Gastaut and Dravet syndrome. Dravet (pronounced Dra-VAY), also known as severe myoclonic epilepsy of infancy, strikes children under 2, typically starts with a high fever, and leads to uncontrollable seizures and cognitive decline. “These children typically do not respond to medication,” Privitera says. “They may lose developmental milestones or even regress in their ability to talk. It’s a terrible disorder.”

Parents of children with serious epilepsy have fueled a demand for legalization of marijuana. But Privitera continues to caution that all drugs must be proven safe, and appropriate doses must be established. “We have to treat it like any other drug,” he says. “We need to know how it works, who will be helped by it, and what side effects it may produce.”

Two important compounds in marijuana are THC (delta-9 tetrahydrocannabinol), which has “psychoactive effects,” and cannabidiol (CBD), which appears to have the most medicinal properties and does not produce psychoactive effects.

“The goal is to get a medication that works for people without making them high,” Privitera says. “You don’t want an 8-year-old who lacks seizure control to be high in class. We’re trying to extract what works for seizures and leave the other stuff behind.”

Epidiolex, the drug used in UC’s study, is made from purified CBD by GW Pharmaceuticals. It was dissolved in oil and squirted into the mouth of patients who participated in the trial. It contained no THC.

A synthetic form of THC called Marinol, which is created in a laboratory, has been approved for patients with cancer or AIDS who suffer severe appetite loss and nausea. “Marinol can make people high,” Privitera notes. A synthetic marijuana also has been approved in Europe (but not the United States) for treating spasticity in patients with multiple sclerosis.

Marijuana, including plant-based CBD, is classified by the U.S. Drug Enforcement Administration (DEA) as a Schedule I drug. The scheduling system is based on a drug’s effectiveness as a medical therapy as well as its potential for abuse and dependency. Schedule 1 drugs, which include heroin and ecstasy, are defined as having “no currently accepted medical use and a high potential for abuse.”

As a result, researchers at the UC Epilepsy Center followed stringent safety requirements in their adult Lennox-Gastaut study. “To conduct our research, I had to acquire special licensing as a ‘terminal distributor of dangerous drugs,’ plus undergo multiple DEA inspections,” Privitera says.

Privitera once quipped that the study medication was “housed in the kind of safe that the Coyote would drop on the Road Runner cartoon character. It’s a 650-pound safe that is kept in a locked room.”

Privitera and others, including the American Medical Association and the American Academy of Pediatrics, agree that reclassifying marijuana or CBD as a lesser schedule would greatly speed research.

— Cindy Starr

This entry was posted in UC Gardner Neuroscience Blog, Uncategorized. Bookmark the permalink. Both comments and trackbacks are currently closed.
  • Print This Page
  • Make an Appointment: Schedule Now
  • Sign up for our newsletter!
  • UCNI Weekly Blog
  • Hope Stories

    • Jim’s Story: Acromegaly / Pituitary Tumor

      Jim's Story: Acromegaly / Pituitary Tumor Four years later, Jim’s story just keeps getting better. Because four years after being treated for a pituitary tumor at the UC Brain Tumor Center, Jim continues to feel better and better. The size of his head has gone down....
    • Scott’s Story: The Epilepsy Ambassador

      Scott's Story: The Epilepsy AmbassadorScott was working his dream job as a commercial airline pilot 10 years ago when his life was forever changed by epilepsy. After coming home from a long run, he complained of nausea and then collapsed with a grand mal...
    • Frank’s Story: Parkinson’s Disease

      Frank's Story: Parkinson's DiseaseSome people have vacation homes. Frank has the UC Gardner Neuroscience Institute. This is where he comes for comprehensive, compassionate medical care for Parkinson’s disease, which he has lived with for 15 years. “They make us feel safe,” says Frank’s wife,...
    • Doug’s Story: Stroke Survivor

      Doug's Story: Stroke SurvivorIt was a weekday evening like any other when a friendly customer service representative named Doug became the ultimate customer. His need? Stroke services, A to Z. Doug, a self-described overweight former smoker with high blood pressure and diabetes, was trying...
    • Amber’s Story: Ruptured Aneurysm

      Amber's Story: Ruptured Aneurysm The only visible sign of Amber Gray’s ordeal is the long slender scar that runs along her forearm. It is the area where a surgeon carefully removed her radial artery, which was needed to bypass a damaged artery in her...
    • Alicia’s Story: Multiple Sclerosis

      Alicia’s Story: Multiple SclerosisAlicia is relishing a life that is filled to the brim: she is a wife, a mother, a runner and a master at living with multiple sclerosis. Diagnosed in the late 1990s, Alicia had “a bumpy ride” in the beginning. But...
    • Charles Sabine’s Story: Huntington’s Disease

      Charles Sabine's Story: Huntington's DiseaseIn 2005 the NBC war correspondent Charles Sabine made the life-altering decision to face up to his family history of Huntington’s disease and undergo genetic testing. The odds, he knew, were 50-50 that he, too, had the gene and would...
    • Mike’s Hope Story: Parkinson’s disease

      Mike's Hope Story: Parkinson's disease Imagine learning you have Parkinson’s Disease. At 26. Most Parkinson’s patients are diagnosed in their 60s. Yet in 1987, after three years of unexplained symptoms, Mike Pohl learned he had the degenerative disease. After a visit to the National Institutes...
    • Charlie’s Story: Epilepsy

      Charlie's Story: EpilepsyBy Charlie Shor I have had many adventures in my 57 years, and I have accomplished much. But the main message of my story, which I have been given the opportunity to share, is that anything is possible. If you have...
    • Deanna’s Story: Conquering Seizures

      Deanna's Story: Conquering SeizuresDeanna was averaging three seizures a week when she arrived at the UC Gardner Neuroscience Institute. Sometimes her seizures caused her to pass out, and sometimes they left her blinking and wondering where the time had gone. Complicating her situation,...